Geranylgeraniol

Geranylgeraniol is an orally acitve vitamin K₂ sub-type, an intermediate of the mevalonate pathway. Geranylgeraniol targets NF-kB signaling pathway and could alleviate LPS-induced microglial inflammation in animal model^[1][2][3][4]. IC50 & Target: NF-kB^[1] In Vitro: Geranylgeraniol (0-10 μM; 24 h) dose-dependently suppresses the LPS-induced increase in the mRNA levels of Il-1β, Tnf-α, Il-6, and Cox-2^[1].
Geranylgeraniol (10 μM; 24 h) inhibits the phosphorylation of TAK1, IKKα/β, and NF-κB p65 proteins as well as NF-κB nuclear translocation induced by LPS while maintaining IκBα expression^[1].
Geranylgeraniol, (50 μM; 24 h) eliminates cell damage caused by Simvastatin (HY-17502) (10 µM) and Mevalonat (10 mM), and reduces the inflammatory marker and the damage of the mitochondria, maintaining its shape and component^[2].
In Vivo: Geranylgeraniol (725 mg/kg/d; p.o.; 90 d) is not toxicologically significant with a dose below 725 mg/kg/d in rats^[3].
Geranylgeraniol (483 mg/kg/d; p.o.; 10 d) suppresses lipopolysaccharide-induced inflammation via inhibition of nuclear factor-κB activation in rats^[4].